d="p0010">Epidermal growth factor receptor inhibitors are believed to overcome/delay breast cancer endocrine resistance.
dd><dt class="label">•dt><dd>d="p0015">Hormone receptor-positive metastatic women were randomized to anastrozole (A) and gefitinib (G) or placebo (P).
dd><dt class="label">•dt><dd>d="p0020">1-Year progression-free survival rate was 35% for A/G and 32% for A/P.
dd><dt class="label">•dt><dd>d="p0025">One-third of G arm patients stopped treatment due to intestinal and skin toxicities.
dd><dt class="label">•dt><dd>d="p0030">Results do not support endocrine resistance delay by adding G to A.
dd>dl>